{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "NCT03060551",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "OutcomeClassDenomCountGroupId",
                  "OutcomeClassDenomCountValue",
                  "OutcomeClassDenomUnits",
                  "OutcomeClassTitle",
                  "OutcomeDenomCountGroupId",
                  "OutcomeDenomCountValue",
                  "OutcomeDenomUnits",
                  "OutcomeGroupDescription",
                  "OutcomeGroupId",
                  "OutcomeGroupTitle",
                  "OutcomeMeasureAnticipatedPostingDate",
                  "OutcomeMeasureCalculatePct",
                  "OutcomeMeasureDenomUnitsSelected",
                  "OutcomeMeasureDescription",
                  "OutcomeMeasureDispersionType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OutcomeClassDenomCountGroupId": [],
                        "OutcomeClassDenomCountValue": [],
                        "OutcomeClassDenomUnits": [],
                        "OutcomeClassTitle": [
                              "baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks",
                              "Baseline",
                              "2 weeks",
                              "6 weeks",
                              "12 weeks",
                              "24 weeks"
                        ],
                        "OutcomeDenomCountGroupId": [
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000"
                        ],
                        "OutcomeDenomCountValue": [
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18",
                              "18"
                        ],
                        "OutcomeDenomUnits": [
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants",
                              "Participants"
                        ],
                        "OutcomeGroupDescription": [
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure.",
                              "Participants received SVF treatment, and were fully followed-up for the whole scheduled period for clinical assessment. SVF extraction and injection were performed in outpatient setting within at least 1 month after baseline evaluation. All patients were regulary assessed for intervention-related adverse events and clinical efficacies at 2 weeks (2W), 6 weeks (6W), 12 weeks (12W) and 24 weeks (24W) after their procedure."
                        ],
                        "OutcomeGroupId": [
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000",
                              "OG000"
                        ],
                        "OutcomeGroupTitle": [
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group",
                              "SVF Injection Group"
                        ],
                        "OutcomeMeasureAnticipatedPostingDate": [],
                        "OutcomeMeasureCalculatePct": [],
                        "OutcomeMeasureDenomUnitsSelected": [],
                        "OutcomeMeasureDescription": [
                              "The severity of Raynaud's phenomenon was assessed using the Raynaud's condition scale (ranging 0 to 10, with higher scores representing more severe Raynaud's phenomenon)",
                              "Hand pain was assessed using the Hand visual analogue scale (ranging 0 to 10, with higher scores representing more severe pain)",
                              "The Colchin hand function scale (CHFS, ranging 0 to 90, with higher scores representing more deteriorated hand function) scores",
                              "Kapandji score (ranging 0 to 10) is validated measures in past studies as outcomes for hand disability. The Kapandji score is a tool useful for assessing the opposition of the thumb, based on where on their hand the patient is able to touch with the tip of their thumb. A score of 0 indicates no opposition, a score of 10 indicates maximal opposition.",
                              "Kapandji score (ranging 0 to 10) is validated measures in past studies as outcomes for hand disability. The Kapandji score is a tool useful for assessing the opposition of the thumb, based on where on their hand the patient is able to touch with the tip of their thumb. A score of 0 indicates no opposition, a score of 10 indicates maximal opposition.",
                              "Disease-related QOL (quality of life) was measured by EuroQol-5 dimensions time trade-off (EQ-5D TTO, ranging 0 to 1, with higher values representing better QOL) values",
                              "Disease-related QOL (quality of life) : EuroQol visual analog scale (EQ VAS, ranging 0 to 100, with higher scores representing better QOL)",
                              "Disease-related QOL (quality of life) : health assessment questionnaire (HAQ, ranging 0 to 3, with higher scores meaning lower QOL)",
                              "The finger circumferences of the second to the fifth fingers measured in the middle portion of each proximal phalanx were used to assess the degree of hand edema",
                              "The finger circumferences of the second to the fifth fingers measured in the middle portion of each proximal phalanx were used to assess the degree of hand edema",
                              "In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented.",
                              "In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented.",
                              "In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented.",
                              "In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented.",
                              "In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented.",
                              "In order to assess the severity of microangiopathies in both fingers, a semiquantitative scoring system for nailfold capillary microscopic findings was adopted. A total of six parameters (irregularly enlarged capillaries, giant capillaries, hemorrhages, loss of capillaries, disorganization of the vascular array and capillary ramifications) were measured using the semiquantitative manner on the scale ranging 0 to 3, indicating more severe as scores were higher. Each parameter was scored for four fingers of both hands, except thumbs, and the median score value of each parameter in both hands was finally presented."
                        ],
                        "OutcomeMeasureDispersionType": [
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range",
                              "Inter-Quartile Range"
                        ],
                        "NCTId": [
                              "NCT03060551"
                        ]
                  }
            ]
      }
}